Provider review
Broose Wellness review
By The Dose Brief Desk · Updated
Broose lists usable four-week prices but unfinished longer-plan price placeholders. Get a complete written offer before selecting more than four weeks.
Not rated. This review examines published program information; it is not a firsthand treatment review.
At a glance
- Semaglutide
- Injection $249/four weeks; oral $279/four weeks
- Tirzepatide
- Injection $339/four weeks
- Availability
- Confirm state eligibility and assigned clinician/pharmacy.
- Treatment formats
- Semaglutide oral and injectable formulations; tirzepatide injections.
Longer-plan cards contain placeholder prices; no reliable three- or six-month total is established.
Four-week prices are the usable comparison
Broose Wellness lists semaglutide injections at $249 per four weeks, oral semaglutide at $279 per four weeks and tirzepatide injections at $339 per four weeks. Those prices apply to different formulations. Four-week periods also differ from calendar months when budgeting over a year.
Longer offers are unfinished
The same page contains three- and six-month cards with dollar placeholders instead of actual totals. Do not interpret an empty savings field as a real discount. Ask for the full offer and the operative terms before authorizing a longer purchase.
What the care description includes
Broose describes medical consultation, a prescription if appropriate and ongoing provider support as part of its plans. The exact dispensing pharmacy, state availability and renewal process were not established by the reviewed page.
A useful decision rule
The four-week route can be compared only after confirming the supplied quantity, formulation and delivery charges. The longer options need clarification first. Obtain the cancellation deadline and what happens if treatment is declined or changed; incomplete sales cards do not answer those questions.
What stands out
- Distinct oral and injectable four-week prices
- Clinical consultation and follow-up are described
What to check
- Longer-term cards contain unresolved placeholders
- Pharmacy and recurring-payment details need confirmation
Sources and review scope
Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.